CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 209 enrolled
Drug / intervention
JUVÉDERM VOLITE™ XCdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03728309
NCT03728309N/ACompleted

Protocol Title: A Randomized, Multicenter, Evaluator-blind, Controlled Study to Evaluate the Safety and Effectiveness of JUVÉDERM VOLITE™ XC Injectable Gel for the Improvement in Cheek Skin Smoothness

Allergan·interventional·Posted Nov 2, 2018·Updated Dec 19, 2022

In Brief

A clinical study evaluating JUVÉDERM VOLITE™ XC for Skin Smoothness of the Cheeks. Completed, enrolled 209 participants across 14 sites in 2 countries.

Detailed Summary

This is a pivotal study to collect safety and effectiveness data on JUVÉDERM VOLITE™ XC for improvement in skin smoothness of the cheeks in order to support FDA product approval.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPuerto Rico, United States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedNov 2, 2018
Enrollment StartNov 9, 2018
Primary CompletionJul 17, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.7 years ago

Interventions

JUVÉDERM VOLITE™ XCdevice

Intradermal, needle in multiple microdepot injections across both cheeks.